MDK and lymphangioleiomyomatosis: We identified MDK as a secreted factor that may promote lymphangiogenesis and angiogenesis in SLS-dominant tumors, and found that MDK is elevated in the serum of LAM patients, suggesting that it may be a critical mechanistic link to lymphangiogenesis in LAM as well as a candidate therapeutic target.